在扩散中线质瘤 (DMG) 中识别分子向治疗诱导的免疫
Niloofar Khairkhah1, Habeebah Owolabi2, Ali Namvar1
1Department of Radiology, The University of Michigan Medical School, Ann Arbor, MI 48109, United States.
概括
这项研究表明,MTX-241F改变了扩散中线质瘤 (DMG) 和质母细胞瘤 (GBM) 的瘤免疫皮组. 它揭示了新的标,如H2B1K和治疗诱导的,用于增强免疫疗法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 具有H3K27M突变的扩散中线质瘤 (DMG) 是一种治疗耐药的儿科脑瘤,免疫可见性差.
- 在DMG中有限的抗原呈现阻碍了有效的免疫识别和治疗策略.
- 了解质瘤生物学和对免疫识别的治疗作用对于识别新的瘤点至关重要.
研究的目的:
- 为了研究在使用选择性EGFR/PI3K抑制剂MTX-241F治疗后扩散中线质瘤 (DMG) 和质母细胞瘤 (GBM) 的免疫变化.
- 为了确定瘤特异性免疫和治疗诱导的变化,可以作为免疫治疗的潜在目标.
- 探索MTX-241F对不同类型质瘤免疫皮组的影响.
主要方法:
- 在DMG和GBM异种移植的人类细胞系衍生瘤组织上进行了免疫瘤学.
- 用质谱学分离和分析了与MHC-I结合的.
- 进行了跨瘤类型 (DMG与GBM) 和治疗条件 (车辆与MTX-241F) 的比较分析.
主要成果:
- 在DMG和GBM之间观察到类谱的显著差异,GBM显示免疫的数量是两倍.
- 在DMG中,H2B1K衍生的免疫是非常丰富的,这表明H3K27M驱动的表体转录体效应.
- MTX-241F在DMG中增加了免疫,但在GBM中降低了免疫,表明瘤特异性免疫调节.
- 大脑丰富,HLA-A*02:01结合,MTX-241F独有的免疫被确定为潜在的生物标志物和CAR-T细胞标.
结论:
- MTX-241F调节质瘤免疫,揭示H2B1K,大脑丰富和治疗诱导的免疫作为可行的标.
- 这些发现支持将向疗法与免疫疗法整合在一起,以改善DMG和GBM的瘤识别和治疗疗效.
- 这项研究强调了已识别的免疫作为治疗反应的生物标志物的潜力.
相关概念视频
Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion
31.4K
Although gaseous molecules travel at tremendous speeds (hundreds of meters per second), they collide with other gaseous molecules and travel in many different directions before reaching the desired target. At room temperature, a gaseous molecule will experience billions of collisions per second. The mean free path is the average distance a molecule travels between collisions. The mean free path increases with decreasing pressure; in general, the mean free path for a gaseous molecule will be...
31.4K
Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
Diffusion
219.9K
Diffusion is the passive movement of substances down their concentration gradients—requiring no expenditure of cellular energy. Substances, such as molecules or ions, diffuse from an area of high concentration to an area of low concentration in the cytosol or across membranes. Eventually, the concentration will even out, with the substance moving randomly but causing no net change in concentration. Such a state is called dynamic equilibrium, which is essential for maintaining overall...
219.9K
Diffusion
6.4K
Diffusion is a type of passive transport. In passive transport, a substance tends to move from an area of high concentration to an area of low concentration until the concentration is equal across the space. For example, take the diffusion of substances through the air. When someone opens a perfume bottle in a room filled with people, the perfume is at its highest concentration in the bottle and is at its lowest at the edges of the room. The perfume vapor will diffuse, or spread away, from the...
6.4K
Facilitated Diffusion
1.3K
The plasma membrane, a critical structure in cellular biology, houses an array of transporters, or carrier proteins, interspersed within its lipid bilayer. These proteins play a crucial role in solute transport through facilitated diffusion, a form of passive diffusion that uses transporters to move the molecules across the membrane.
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...
1.3K
Gene Therapy
27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K


